drugset / Trial / NCT04610541

REMdesivir-HU Clinical Study and Severe Covid-19 Patients

NCT04610541

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.

Timeline

Start
2020-10-12
Primary completion
2021-10-30
Completion
2021-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Remdesivir Small molecule 100 mg Intravenous

Indications